1. Home
  2. SKYE vs WHF Comparison

SKYE vs WHF Comparison

Compare SKYE & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • WHF
  • Stock Information
  • Founded
  • SKYE 2012
  • WHF N/A
  • Country
  • SKYE United States
  • WHF United States
  • Employees
  • SKYE N/A
  • WHF N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • WHF Finance Companies
  • Sector
  • SKYE Health Care
  • WHF Finance
  • Exchange
  • SKYE Nasdaq
  • WHF Nasdaq
  • Market Cap
  • SKYE 176.8M
  • WHF 303.3M
  • IPO Year
  • SKYE N/A
  • WHF 2012
  • Fundamental
  • Price
  • SKYE $6.31
  • WHF $12.26
  • Analyst Decision
  • SKYE Strong Buy
  • WHF Hold
  • Analyst Count
  • SKYE 4
  • WHF 3
  • Target Price
  • SKYE $19.25
  • WHF $12.75
  • AVG Volume (30 Days)
  • SKYE 416.2K
  • WHF 92.5K
  • Earning Date
  • SKYE 01-01-0001
  • WHF 08-08-2024
  • Dividend Yield
  • SKYE N/A
  • WHF 12.52%
  • EPS Growth
  • SKYE N/A
  • WHF 7.89
  • EPS
  • SKYE N/A
  • WHF 0.82
  • Revenue
  • SKYE N/A
  • WHF $102,571,000.00
  • Revenue This Year
  • SKYE N/A
  • WHF N/A
  • Revenue Next Year
  • SKYE N/A
  • WHF N/A
  • P/E Ratio
  • SKYE N/A
  • WHF $14.94
  • Revenue Growth
  • SKYE N/A
  • WHF 9.52
  • 52 Week Low
  • SKYE $1.44
  • WHF $11.48
  • 52 Week High
  • SKYE $19.41
  • WHF $13.69
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 36.78
  • WHF 41.09
  • Support Level
  • SKYE $5.95
  • WHF $12.25
  • Resistance Level
  • SKYE $6.83
  • WHF $12.44
  • Average True Range (ATR)
  • SKYE 0.94
  • WHF 0.18
  • MACD
  • SKYE 0.09
  • WHF 0.01
  • Stochastic Oscillator
  • SKYE 33.23
  • WHF 27.69

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate attractive risk-adjusted returns for investors, primarily by originating senior secured loans to privately held small-cap companies across a broad range of industries.

Share on Social Networks: